The Latest Cardiac and Vascular News
Successfully launched CAPLYTA® (lumateperone) in late March 2020 and demonstrated strong commercial execution in the midst of COVID-19. CAPLYTA achieved net product revenues of $12.4 million and $22.5 million for fourth quarter and full year 2020, respectively. Fourth quarter CAPLYTA total prescriptions (TRx) increased 77% versus the previous quarter. Pursuing CAPLYTA […]
Successful disposition will facilitate continued strategic focus on high-value late-stage biopharma asset JAN101 for the treatment of peripheral artery disease (PAD) LAS VEGAS, Feb. 25, 2021 /PRNewswire/ — JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, today announced that is […]
BGF announces multi-million investment in Vasorum – high-growth medical device business based in Dublin Ireland DUBLIN, IRELAND, February 25, 2021 /EINPresswire.com/ — BGF announces multi-million investment in Vasorum – high-growth Medical device business based in Dublin 7th Irish investment by BGF in 2 years Thursday 25th February 2021 BGF – […]
LONDON–(BUSINESS WIRE)–LivaNova PLC (NASDAQ: LIVN), a market-leading medical technology and innovation company, today reported results for the quarter and full-year ended December 31, 2020. For the fourth quarter of 2020, worldwide sales from continuing operations were $269.6 million, a decrease of 6.3 percent on a reported basis and a decline […]
– Transaction furthers Terumo’s efforts to improve patient outcomes and decrease healthcare costs through personalized predictive analytics and clinical decision support at the point of care – TOKYO, Feb. 23, 2021 /PRNewswire/ — Terumo Corporation (TSE: 4543), a global leader in medical technology, has signed a definitive agreement to acquire all […]
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Feb. 24, 2021 /PRNewswire/ — United Therapeutics Corporation (Nasdaq: UTHR) today announced its financial results for the fourth quarter and year ended December 31, 2020. Full year net revenue rose to $1,483 million, as U.S. patients being treated with the company’s treprostinil-based therapies reached an all-time high during the […]
Fourth Quarter 2020 U.S. Product Revenue of $8.2 Million, Approximately 150 Percent Increase Compared to the Third Quarter Over 21,000 Patients on NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Tablets in the U.S. CLEAR Outcomes Study Design Highlighted in The American Heart Journal and Progresses Uninterrupted Despite Pandemic […]
– Significant pipeline progress with potentially first- or best-in-class drug candidates – Strong cash position of $1.1 billion as of December 31, 2020 SAN DIEGO–(BUSINESS WIRE)–Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2020. “This […]
– Q3 Revenue of $7.8 Billion Increased 0.8% as Reported and Decreased 1.0% Organically – Q3 GAAP Diluted EPS of $0.94; Q3 Non-GAAP Diluted EPS of $1.29 DUBLIN, Feb. 23, 2021 /PRNewswire(opens new window)/ — Medtronic plc (NYSE:MDT) today announced financial results for its third quarter of fiscal year 2021, which ended January 29, 2021. The company reported […]
SAN CARLOS, Calif., Feb. 23, 2021 (GLOBE NEWSWIRE) — BioCardia®, Inc. [Nasdaq: BCDA], today announced that it has entered into an agreement with a leading Japanese pharmaceutical company related to BioCardia Helix catheter biotherapeutic delivery product candidates. Under the terms of the agreement, BioCardia will receive a $500,000 up-front payment, a portion […]
